BackTable Urology
Ep. 193 Bladder Cancer Innovations: ESMO 2024 Highlights with Dr. Andrea Apolo
Dr. Andrea Apolo
Those are the patients that I get super nervous about because although they do respond well to platinum-based chemotherapy, they respond well to checkpoint inhibitors. They do have a higher rate of positive margins. They have a higher rate of recurrence. And I don't know how to better manage them with the therapies that we have right now without prospectively testing them.
0
💬
0
Comments
Log in to comment.
There are no comments yet.